Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.…
Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio (NASDAQ: RLYB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 15.47 USD on 20 November 2026, up 202.6% over 52 weeks. Its 52-week range is 3.670 USD to 17.57 USD: the price is 12.0% below the high and 321.5% above the low.
At a market capitalisation of 86.63M USD, it trades at 3.4 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 90% for RLYB.
Rallybio reports return on equity of -15.5%.
It holds more cash than debt, a net cash position of 90.69M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.